This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
62
10 mg/mL of semaglutide solution for s.c. injection, single dose
Novo Nordisk Investigational Site
Miami, Florida, United States
Novo Nordisk Investigational Site
Orlando, Florida, United States
Novo Nordisk Investigational Site
Knoxville, Tennessee, United States
AUC of NN9535
Time frame: at 21 days
Laboratory safety, adverse events
Time frame: at 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.